These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1685 related items for PubMed ID: 28486985

  • 1. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ, Hung JY, Tsai MJ, Wu KL, Liu TC, Chou SH, Lee JY, Hsu JS, Huang MS, Chong IW.
    BMC Pharmacol Toxicol; 2017 May 10; 18(1):21. PubMed ID: 28486985
    [Abstract] [Full Text] [Related]

  • 2. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH, Tseng YC, Lin YH, Lee YC, Perng RP, Whang-Peng J, Chen YM.
    Oncologist; 2015 Jul 10; 20(7):758-66. PubMed ID: 26054633
    [Abstract] [Full Text] [Related]

  • 3. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
    Han JY, Lee KH, Kim SW, Min YJ, Cho E, Lee Y, Lee SH, Kim HY, Lee GK, Nam BH, Han H, Jung J, Lee JS.
    Cancer Res Treat; 2017 Jan 10; 49(1):10-19. PubMed ID: 27188206
    [Abstract] [Full Text] [Related]

  • 4. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J, Zhang L, Zhu H, Pan W, Zhang N, Li Y, Yang M.
    DNA Cell Biol; 2018 Nov 10; 37(11):903-908. PubMed ID: 30277797
    [Abstract] [Full Text] [Related]

  • 5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 6. Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.
    Lai SW, Ho CL, Dai MS, Chen WL, Chang PY, Wu YY, Perng CL, Lai CY.
    J BUON; 2014 May 25; 19(2):459-65. PubMed ID: 24965407
    [Abstract] [Full Text] [Related]

  • 7. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH.
    Lung Cancer; 2014 May 25; 84(2):196-202. PubMed ID: 24629638
    [Abstract] [Full Text] [Related]

  • 8. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, Shen CH, Kuo TY, Lee JY, Chou SH, Liu TC, Chong IW, Huang MS.
    Lung Cancer; 2015 May 25; 88(2):187-94. PubMed ID: 25747806
    [Abstract] [Full Text] [Related]

  • 9. Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment.
    Yang CJ, Tsai MJ, Hung JY, Liu TC, Chou SH, Lee JY, Hsu JS, Tsai YM, Huang MS, Chong IW.
    Onco Targets Ther; 2016 May 25; 9():1579-87. PubMed ID: 27051298
    [Abstract] [Full Text] [Related]

  • 10. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC, Tseng GC, Tu CY, Chen WC, Liao WC, Chen WC, Li CH, Chen HJ, Hsia TC.
    Lung Cancer; 2017 Aug 25; 110():56-62. PubMed ID: 28676220
    [Abstract] [Full Text] [Related]

  • 11. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
    Liam CK, Ruthranesan M, Lee CH, Pang YK, Chua KT, Lim BK.
    Asia Pac J Clin Oncol; 2012 Sep 25; 8(3):267-74. PubMed ID: 22897510
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
    Yang CJ, Tsai MJ, Hung JY, Lee MH, Tsai YM, Tsai YC, Hsu JF, Liu TC, Huang MS, Chong IW.
    BMC Pharmacol Toxicol; 2017 Dec 13; 18(1):82. PubMed ID: 29237484
    [Abstract] [Full Text] [Related]

  • 14. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G, Xie X, Sun D, Geng J, Fu F, Zhang L, Wang H.
    Int J Clin Exp Pathol; 2015 Dec 13; 8(7):8603-6. PubMed ID: 26339441
    [Abstract] [Full Text] [Related]

  • 15. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr 13; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
    He P, Wang Y, Yang S, Yu S, Wang Z, Li J, Wang B, Hao X, Wang H, Hu X, Zhang X, Shi Y.
    Zhongguo Fei Ai Za Zhi; 2013 Oct 20; 16(10):529-34. PubMed ID: 24113006
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat.
    Ont Health Technol Assess Ser; 2010 Oct 20; 10(24):1-48. PubMed ID: 23074402
    [Abstract] [Full Text] [Related]

  • 19. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.
    J Clin Oncol; 2011 Jul 20; 29(21):2866-74. PubMed ID: 21670455
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y, Huang ZY, Yu HF, Luo LH.
    Zhonghua Zhong Liu Za Zhi; 2010 Nov 20; 32(11):859-63. PubMed ID: 21223694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 85.